Literature DB >> 31197017

Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts.

Mohan Bolisetty1,2, Pasquale Laise3, William F Flynn1, Ela Elyada4,5, Elise T Courtois1, Richard A Burkhart6, Jonathan A Teinor6, Pascal Belleau4, Giulia Biffi4,5, Matthew S Lucito4,5, Santhosh Sivajothi1, Todd D Armstrong6, Dannielle D Engle4,5,7, Kenneth H Yu8, Yuan Hao4, Christopher L Wolfgang6, Youngkyu Park4,5, Jonathan Preall4, Elizabeth M Jaffee6, Andrea Califano3,9,10,11,12, Paul Robson13,14, David A Tuveson15,5.   

Abstract

Cancer-associated fibroblasts (CAF) are major players in the progression and drug resistance of pancreatic ductal adenocarcinoma (PDAC). CAFs constitute a diverse cell population consisting of several recently described subtypes, although the extent of CAF heterogeneity has remained undefined. Here we use single-cell RNA sequencing to thoroughly characterize the neoplastic and tumor microenvironment content of human and mouse PDAC tumors. We corroborate the presence of myofibroblastic CAFs and inflammatory CAFs and define their unique gene signatures in vivo. Moreover, we describe a new population of CAFs that express MHC class II and CD74, but do not express classic costimulatory molecules. We term this cell population "antigen-presenting CAFs" and find that they activate CD4+ T cells in an antigen-specific fashion in a model system, confirming their putative immune-modulatory capacity. Our cross-species analysis paves the way for investigating distinct functions of CAF subtypes in PDAC immunity and progression. SIGNIFICANCE: Appreciating the full spectrum of fibroblast heterogeneity in pancreatic ductal adenocarcinoma is crucial to developing therapies that specifically target tumor-promoting CAFs. This work identifies MHC class II-expressing CAFs with a capacity to present antigens to CD4+ T cells, and potentially to modulate the immune response in pancreatic tumors.See related commentary by Belle and DeNardo, p. 1001.This article is highlighted in the In This Issue feature, p. 983. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31197017      PMCID: PMC6727976          DOI: 10.1158/2159-8290.CD-19-0094

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  85 in total

1.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Authors:  S Onizuka; I Tawara; J Shimizu; S Sakaguchi; T Fujita; E Nakayama
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

2.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

Authors:  J Shimizu; S Yamazaki; S Sakaguchi
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

Authors:  Sunil R Hingorani; Lifu Wang; Asha S Multani; Chelsea Combs; Therese B Deramaudt; Ralph H Hruban; Anil K Rustgi; Sandy Chang; David A Tuveson
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

5.  XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor.

Authors:  H Yoshida; T Matsui; A Yamamoto; T Okada; K Mori
Journal:  Cell       Date:  2001-12-28       Impact factor: 41.582

6.  Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Jeffrey R Lee; Kanchan G Jhaver; Theodore S Johnson; Derin B Keskin; Brendan Marshall; Phillip Chandler; Scott J Antonia; Russell Burgess; Craig L Slingluff; Andrew L Mellor
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

7.  T-cell engagement of dendritic cells rapidly rearranges MHC class II transport.

Authors:  Marianne Boes; Jan Cerny; Ramiro Massol; Marjolein Op den Brouw; Tom Kirchhausen; Jianzhu Chen; Hidde L Ploegh
Journal:  Nature       Date:  2002-08-29       Impact factor: 49.962

8.  ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context.

Authors:  Adam A Margolin; Ilya Nemenman; Katia Basso; Chris Wiggins; Gustavo Stolovitzky; Riccardo Dalla Favera; Andrea Califano
Journal:  BMC Bioinformatics       Date:  2006-03-20       Impact factor: 3.169

9.  Increase in decorin and biglycan in Duchenne Muscular Dystrophy: role of fibroblasts as cell source of these proteoglycans in the disease.

Authors:  Ricardo Fadic; Valeria Mezzano; Karin Alvarez; Daniel Cabrera; Jenny Holmgren; Enrique Brandan
Journal:  J Cell Mol Med       Date:  2006 Jul-Sep       Impact factor: 5.310

10.  Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.

Authors:  Kai Hildner; Brian T Edelson; Whitney E Purtha; Mark Diamond; Hirokazu Matsushita; Masako Kohyama; Boris Calderon; Barbara U Schraml; Emil R Unanue; Michael S Diamond; Robert D Schreiber; Theresa L Murphy; Kenneth M Murphy
Journal:  Science       Date:  2008-11-14       Impact factor: 47.728

View more
  350 in total

Review 1.  Lipid Metabolism in Tumor-Associated Fibroblasts.

Authors:  Hongzhong Li; Jingyuan Wan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

3.  IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions.

Authors:  Gianluca Mucciolo; Claudia Curcio; Cecilia Roux; Wanda Y Li; Michela Capello; Roberta Curto; Roberto Chiarle; Daniele Giordano; Maria Antonietta Satolli; Rita Lawlor; Aldo Scarpa; Pavol Lukac; Dmitry Stakheev; Paolo Provero; Luca Vannucci; Tak W Mak; Francesco Novelli; Paola Cappello
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

4.  Cancer associated fibroblast: Mediators of tumorigenesis.

Authors:  Jennifer Alexander; Edna Cukierman
Journal:  Matrix Biol       Date:  2020-05-22       Impact factor: 11.583

5.  Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas.

Authors:  Reuben Moncada; Dalia Barkley; Florian Wagner; Marta Chiodin; Joseph C Devlin; Maayan Baron; Cristina H Hajdu; Diane M Simeone; Itai Yanai
Journal:  Nat Biotechnol       Date:  2020-01-13       Impact factor: 54.908

6.  Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.

Authors:  Tongtong Wei; Jinjing Song; Kai Liang; Li Li; Xiaoxiang Mo; Zhiguang Huang; Gang Chen; Naiquan Mao; Jie Yang
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-02       Impact factor: 4.553

7.  A map of human breast cancer: new players in stromal-immune crosstalk.

Authors:  Kathleen M McAndrews; Raghu Kalluri
Journal:  EMBO J       Date:  2020-09-10       Impact factor: 11.598

Review 8.  Advancing Cancer Research and Medicine with Single-Cell Genomics.

Authors:  Bora Lim; Yiyun Lin; Nicholas Navin
Journal:  Cancer Cell       Date:  2020-04-13       Impact factor: 31.743

Review 9.  GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets.

Authors:  Krishna Sriram; Cristina Salmerón; Shu Z Wiley; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

Review 10.  The mesenchymal context in inflammation, immunity and cancer.

Authors:  Vasiliki Koliaraki; Alejandro Prados; Marietta Armaka; George Kollias
Journal:  Nat Immunol       Date:  2020-08-03       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.